BioSpace News Archive

This morning, multiple companies announced hundreds of millions of dollars were raised in Series B rounds that will be used to advance therapeutics and business development programs.

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is pleased to announce it has received UK Continuing Professional Development (“CPD”) accreditation for Khiron Academy, the Company’s global medical cannabis education platform.

Lixte Biotechnology Holdings, Inc. (“Lixte” or the “Company”) ( Nasdaq: LIXT ), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, announced the appointment of Gil N Schwartzberg to its Board of Directors. Mr. Schwartzberg is filling a vacancy created by the resignation of Winson (Sze Chun) Ho, M.D.

LARVOL , leading provider of data and intelligence solutions for the pharmaceutical and biotech industry, today announced the launch of VIEW , the first curated social listening and sentiment analysis platform focused on Twitter-verified oncologists

Qosina, a global supplier of OEM single-use components to the medical and pharmaceutical industries, is pleased to announce a new extension to their product portfolio, developed specifically for the needs of the single-use bioprocess industry. Qosina now offers a comprehensive selection of components for the design, development and manufacture of single-use systems (SUS).

Survey Commissioned by the Alberta Association of Optometrists Finds Increased Screen Time Fueling Alberta Parents’ Concerns Around Children’s Eye Health

- Preclinical study evaluated melanocortin 1 receptor (MC1R) as a potential target for MC1R-targeted therapies for metastatic melanoma, the lead target of VMT01 - - Results indicate that MC1R-targeted therapies, such as VMT01, are a promising alternative to current therapies for metastatic melanoma - - Company is launching Phase 1 imaging study of VMT01 imminently with provisional results expected in Q4 2021, followed by Phase 1/2a therapy study for the treatment of metastatic mela

All viruses - including SARS-CoV-2, the virus that causes COVID-19 - evolve over time.

Webster Dental Care, an industry-leading dental service organization with eleven locations, welcomes Dr. Peter Faith to its expert team.

Ambry Genetics Corporation announced it will be presenting The Uniform Application of Protein Functional Data has an Impressive Potential to Resolve VUS Rates in BRCA2 based on a study published in The American Journal of Human Genetics in collaboration with researchers at the Mayo Clinic, Moffit Cancer, and the University of Utah.